Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Daraxonrasib (RMC-6236) in Patients With Relapsed or Refractory RAS-Driven Tumors

NCT07819838 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT07819838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07819838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Daraxonrasib (RMC-6236) in Patients With Relapsed or Refractory RAS-Driven Tumors
Lead sponsor
Children's Oncology Group
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
April 9, 2027
Completion date
April 9, 2032
Enrollment
77 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent childhood malignant solid neoplasm, recurrent childhood neuroblastoma, recurrent childhood rhabdomyosarcoma, refractory childhood malignant solid neoplasm, refractory childhood neuroblastoma, refractory childhood rhabdomyosarcoma